{
    "clinical_study": {
        "@rank": "75422", 
        "arm_group": [
            {
                "arm_group_label": "Experimental 1", 
                "arm_group_type": "Experimental", 
                "description": "High dose ONO-4053"
            }, 
            {
                "arm_group_label": "Cetirizine", 
                "arm_group_type": "Active Comparator", 
                "description": "10mg Cetirizine"
            }, 
            {
                "arm_group_label": "Experimental 2", 
                "arm_group_type": "Experimental", 
                "description": "Low dose ONO-4053"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate if ONO-4053 relieves symptoms of allergic\n      rhinitis in seasonal allergic rhinitis subjects exposed to pollen under controlled\n      conditions."
        }, 
        "brief_title": "Phase II Study Evaluating ONO-4053 and Cetirizine in Subjects With Seasonal Allergic Rhinitis", 
        "condition": "Seasonal Allergic Rhinitis", 
        "condition_browse": {
            "mesh_term": [
                "Rhinitis, Allergic, Seasonal", 
                "Rhinitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to investigate if ONO-4053 will impact allergic rhinitis\n      symptoms in subjects with seasonal allergic rhinitis when they are exposed to pollen\n      administered at a fixed rate in an inhalation exposure chamber compared to the standard\n      treatment Cetirizine 10mg under the same conditions."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject is aged between 18 and 65 years inclusive, and healthy with the exception\n             of allergic rhinitis or mild asthma that does not require treatment and has provided\n             written informed consent, which signifies an agreement to enter the study and comply\n             with the restrictions and requirements listed in the informed consent form.\n\n          -  The subject exhibits a moderate to severe response to grass pollen grains in the\n             allergen challenge chamber at Screening.\n\n        Exclusion Criteria:\n\n          -  The subject on examination is found to have nasal structural abnormalities or nasal\n             polyps; a history of frequent nose bleeds, nasal biopsy, nasal trauma or nasal\n             surgery.\n\n          -  Pregnant or breast-feeding females."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01748344", 
            "org_study_id": "ONO-4053POE003"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cetirizine", 
                "description": "10mg tablets", 
                "intervention_name": "Cetirizine", 
                "intervention_type": "Drug", 
                "other_name": "Cetirizine"
            }, 
            {
                "arm_group_label": "Experimental 1", 
                "description": "Experimental", 
                "intervention_name": "High dose ONO-4053", 
                "intervention_type": "Drug", 
                "other_name": "Experimental 1"
            }, 
            {
                "arm_group_label": "Experimental 2", 
                "description": "Experimental", 
                "intervention_name": "Low dose ONO-4053", 
                "intervention_type": "Drug", 
                "other_name": "Experimental 2"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "None active", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cetirizine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Vienna", 
                    "country": "Austria"
                }, 
                "name": "Vienna Clinical Site"
            }
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomised, Placebo Controlled, Four Period Crossover Study to Evaluate the Efficacy, Safety of Oral Repeat Doses of ONO-4053 and Cetirizine in Subjects With Seasonal Allergic Rhinitis in the Vienna Challenge Chamber.", 
        "overall_official": {
            "affiliation": "Ono Pharmaceutical Co. Ltd", 
            "last_name": "Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Austria: Ethikkommission", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To investigate the effect of repeat oral doses of ONO-4053 versus placebo on nasal symptoms elicited by allergen chamber challenge in subjects with seasonal allergic rhinitis.", 
            "measure": "Total Nasal Symptom Score", 
            "safety_issue": "No", 
            "time_frame": "4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01748344"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To investigate the effect of repeat oral doses of ONO-4053 versus Cetirizine on nasal symptoms (Total Nasal Symptom Score) elicited by allergen chamber challenge in subjects with allergic rhinitis.", 
                "measure": "Total Nasal Symptom Score", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }, 
            {
                "description": "Itching and ocular discharge monitored daily", 
                "measure": "Total Ocular Symptom Score", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }, 
            {
                "description": "AUE (0-2h, 2-6h and 0-6h)", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 8"
            }
        ], 
        "source": "Ono Pharmaceutical Co. Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ono Pharmaceutical Co. Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}